Synthesis and evaluation of heterocyclic catechol mimics as inhibitors of catechol-o-methyltransferase (COMT)

ACS Medicinal Chemistry Letters

Volumn 6, Issue 3, 2015, Pages 318-323

  Harrison, Scott T ^a   Poslusney, Michael S ^a,e   Mulhearn, James J ^a   Zhao, Zhijian ^a   Kett, Nathan R ^a   Schubert, Jeffrey W ^a   Melamed, Jeffrey Y ^a   Allison, Timothy J ^b   Patel, Sangita B ^b   Sanders, John M ^c   Sharma, Sujata ^b   Smith, Robert F ^b   Hall, Dawn L ^b   Robinson, Ronald G ^d   Sachs, Nancy A ^d   Hutson, Pete H ^d   Wolkenberg, Scott E ^a   Barrow, James C ^a,e  

^a Department of Medicinal Chemistry ^*  (United States)

^b Global Structural Biology   (United States)

^c Chemical Modeling and Informatics   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

catechol mimic; Catechol O methyl transferase; cognition; schizophrenia

Indexed keywords

3 HYDROXY 4 PYRIDINONE DERIVATIVE; 5 HYDROXY 4 PYRIMIDINONE DERIVATIVE; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; HETEROCYCLIC CATECHOL; MAGNESIUM; S ADENOSYLMETHIONINE; TOLCAPONE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; PRIORITY JOURNAL; X RAY;

EID: 84924679675     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500502d     Document Type: Article

References (36)

1. Saha, S.; Chant, D.; Welham, J.; McGrath, J. A systematic review of the prevalence of schizophrenia PLoS Med. 2005, 2, 413-433
2. Mueser, K. T.; McGurk, S. R. Schizophrenia Lancet 2004, 363, 2063-2072
3. Mackin, R. S.; Delucchi, K. L.; Bennett, R. W.; Arean, P. A. The effect of cognitive impairment on mental healthcare costs for individuals with severe psychiatric illness Am. J. Geriatr. Psychiatry 2011, 19, 176-184
4. Williams, M.; Enna, S. J. Prospects for neurodegenerative and psychiatric disorder drug discovery Expert Opin. Drug Discovery 2011, 6, 457-463
5. Howes, O. D.; Kapur, S. The dopamine hypothesis of schizophrenia: version III-the final common pathway Schizophrenia Bull. 2009, 35, 549-562
6. Goldman-Rakic, P. S.; Castner, S. A.; Svensson, T. H.; Siever, L. J.; Williams, G. V. Targeting the dopamine D-1 receptor in schizophrenia: insights for cognitive dysfunction Psychopharmacology 2004, 174, 3-16
7. Ciliax, B. J.; Heilman, C.; Demchyshyn, L. L.; Pristupa, Z. B.; Ince, E.; Hersch, S. M.; Niznik, H. B.; Levey, A. I. The dopamine transporter: immunochemical characterization and localization in brain J. Neurosci. 1995, 15, 1714-1723
8. Kaenmaki, M.; Tammimaki, A.; Myohanen, T.; Pakarinen, K.; Amberg, C.; Karayiorgou, M.; Gogos, J. A.; Mannisto, P. T. Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice J. Neurochem. 2010, 114, 1745-55
9. Yavich, L.; Forsberg, M. M.; Karayiorgou, M.; Gogos, J. A.; Mannisto, P. T. Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum J. Neurosci. 2007, 27, 10196-10202
10. Fohey, K. D.; Hieber, R.; Nelson, L. A. The role of selegiline in the treatment of negative symptoms associated with schizophrenia Ann. Pharmacother. 2007, 41, 851-856
11. Reenila, I.; Mannisto, P. T. Catecholamine metabolism in the brain by membrane-bound and soluble catechol-o-methyltransferase (COMT) estimated by enzyme kinetic values Med. Hypotheses 2001, 57, 628-632
12. Tunbridge, E. M.; Bannerman, D. M.; Sharp, T.; Harrison, P. J. Catechol-O-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex J. Neurosci. 2004, 24, 5331-5335
13. Egan, M. F.; Goldberg, T. E.; Kolachana, B. S.; Callicott, J. H.; Mazzanti, C. M.; Straub, R. E.; Goldman, D.; Weinberger, D. R. Effect of COMT Val(108/158) Met genotype on frontal lobe function and risk for schizophrenia Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 6917-6922
14. Tsapakis, E. M.; Giakoumaki, S.; Roussos, P.; Chrysoulaki, A.; Kopsahili, I.; Koudas, V.; Bitsios, P. One week tolcapone treatment in psychotic patients: effects on gating, working memory and clinical picture Schizophrenia Res. 2010, 117, 493-493
15. Learmonth, D. A.; Kiss, L. E.; Soares-da Silva, P. The chemistry of catechol O-methyltransferase inhibitors Int. Rev. Neurobiol. 2010, 95, 119-162
16. Kiss, L. E.; Soares-da Silva, P. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility J. Med. Chem. 2014, 57, 8692-8717
17. Bonifacio, M. J.; Palma, P. N.; Almeida, L.; Soares-Da-Silva, P. Catechol-O-methyltransferase and its inhibitors in Parkinsons disease CNS Drug Rev. 2007, 13, 352-379
18. Russ, H.; Muller, T.; Woitalla, D.; Rahbar, A.; Hahn, J.; Kuhn, W. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects Naunyn-Schmiedebergs Arch. Pharmacol. 1999, 360, 719-720
19. Olanow, C. W.; Watkins, P. B. Tolcapone Clin. Neuropharmacol. 2007, 30, 287-294
20. Parashos, S. A.; Wielinski, C. L.; Kern, J. A. Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease Clin. Neuropharmacol. 2004, 27, 119-123
21. Abdolmaleky, H. M.; Cheng, K. H.; Faraone, S. V.; Wilcox, M.; Glatt, S. J.; Gao, F. M.; Smith, C. L.; Shafa, R.; Aeali, B.; Carnevale, J.; Pan, H. J.; Papageorgis, P.; Ponte, J. F.; Sivaraman, V.; Tsuang, M. T.; Thiagalingam, S. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder Hum. Mol. Genet. 2006, 15, 3132-3145
22. Chen, J.; Song, J.; Yuan, P.; Tian, Q.; Ji, Y.; Ren-Patterson, R.; Liu, G.; Sei, Y.; Weinberger, D. R. Orientation and cellular distribution of membrane-bound catechol-o-methyltransferase in cortical neurons: implications for drug development J. Biol. Chem. 2011, 286, 34752-34760
23. Kurkela, M.; Siiskonen, A.; Finel, M.; Tammela, P.; Taskinen, J.; Vuorela, P. Microplate screening assay to identify inhibitors of human catechol-O-methyltransferase Anal. Biochem. 2004, 331, 198-200
24. Borchard, R. T. Catechol O-Methyltransferase 4. In-Vitro Inhibition by 3-hydroxy-4-pyrones, 3-hydroxy-2-pyridones, and 3-hydroxy-4-pyridones J. Med. Chem. 1973, 16, 581-583
25. Monks, T. J.; Jones, D. C. The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers Curr. Drug Metab. 2002, 3, 425-438
26. Robinson, R. G.; Smith, S. M.; Wolkenberg, S. E.; Kandebo, M.; Yao, L. H.; Gibson, C. R.; Harrison, S. T.; Polsky-Fisher, S.; Barrow, J. C.; Manley, P. J.; Mulhearn, J. J.; Nanda, K. K.; Schubert, J. W.; Trotter, B. W.; Zhao, Z. J.; Sanders, J. M.; Smith, R. F.; McLoughlin, D.; Sharma, S.; Hall, D. L.; Walker, T. L.; Kershner, J. L.; Bhandari, N.; Hutson, P. H.; Sachs, N. A. Characterization of non-nitrocatechol Pan and isoform specific catechol-O-methyltransferase inhibitors and substrates ACS Chem. Neurosci. 2012, 3, 129-140
27. Ehler, A.; Benz, J.; Schlatter, D.; Rudolph, M. G. Mapping the conformational space accessible to catechol-O-methyltransferase Acta Crystallogr. Sect. D: Biol. Crystallogr. 2014, 70, 2163-2174
28. Atkinson, J. G.; Girard, Y.; Rokach, J.; Rooney, C. S.; McFarlane, C. S.; Rackham, A.; Share, N. N. Kojic amine-a novel gamma-aminobutyric acid analogue J. Med. Chem. 1979, 22, 99-106
29. Ozturk, G.; Erol, D. D.; Aytemir, M. D.; Uzbay, T. New analgesic and antiinflammatory agents 4(1H)-pyridinone derivatives Eur. J. Med. Chem. 2002, 37, 829-834
30. Ellermann, M.; Lerner, C.; Burgy, G.; Ehler, A.; Bissantz, C.; Jakob-Roetne, R.; Paulini, R.; Allemann, O.; Tissot, H.; Grunstein, D.; Stihle, M.; Diederich, F.; Rudolph, M. G. Catechol-O-methyltransferase in complex with substituted 3-deoxyribose bisubstrate inhibitors Acta Crystallogr. Sect. D: Biol. Crystallogr. 2012, 68, 253-260
31. Wustrow, D. J.; Wierenga, W. Synthesis of a 3-acetoxy-6-phenylpyrone and its conversion to a pyrido[1,4]benzodiazepine Heterocycles 1989, 29, 1721-1728
32. Bai, H. W.; Shim, J. Y.; Yu, J.; Zhu, B. T. Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltransferases Chem. Res. Toxicol. 2007, 20, 1409-1425
33. Vidgren, J.; Svensson, L. A.; Liljas, A. Crystal structure of catechol O -methyltransferase Nature 1994, 368, 354-358
34. Trippier, P. C.; McGuigan, C. Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications Med. Chem. Commun. 2010, 1, 183-198
35. Hansch, C.; Leo, A.; Taft, R. W. A survey of Hammett substituent constants and resonance and field parameters Chem. Rev. 1991, 91, 165-195
36. Cerecor Acquires Rights to Merck COMT Inhibitors. http://www.cerecor.com/news-publications/news-3-20-2013.php.